Background: the diagnosis of cerebral small vessel disease, a leading cause of vascular dementia (VaD), relies solely on neuroimaging studies. Circulating microRNAs (miRNAs) have been proposed as diagnostic biomarkers in various disorders. Our aim was to identify differentially expressed, circulating miRNAs in small vessel VaD which could serve as diagnostic biomarkers for this disease. Method: we performed plasma miRNA profiling by quantitative polymerase chain reaction (qPCR) array in small vessel VaD patients and age-and gender-matched, cognitively normal and healthy controls. Selected, differentially expressed miRNAs were validated by qPCR. Sensitivity, specificity and area under the curve (AUC) were calculated for each individual miRNA. Results: profiling results showed that 44 miRNAs were differentially expressed in small vessel VaD cases (P < 0.05 with a fold change of <2 or >2). A set of seven, highly differentially expressed miRNAs (fold change of <3.6 or >3.6), were estimated in a cohort of 204 small vessel VaD patients and 200 healthy, age and gender-matched controls. Validation study revealed that four miRNAs (miR-409-3p, miR-502-3p, miR-486-5p and miR-451a) could be used as valuable biomarkers for identifying the disease. Sensitivity, specificity and AUC for these miRNAs were 76, 75, 75 and 70%; 89, 89, 83 and 75% and 0.94, 0.92, 0.90 and 0.86, respectively. However, combined receiver operating characteristic curve analysis of seven miRNAs revealed an AUC of 0.64 with sensitivity of 55.5% and specificity of 65.7%. Conclusion: plasma miR-409-3p, miR-502-3p, miR-486-5p and miR-451a could be used to differentiate small vessel VaD patients from healthy controls. Large-scale studies of their biomarker potential are warranted.
Introduction
Cerebral small vessel disease (SVD) which refers to diverse pathological processes affecting small arteries, arterioles, capillaries and venules of the brain [1] , is the most common cause of vascular dementia (VaD) and cognitive decline in older persons [2] . It is also associated with 25% of ischaemic strokes [3] , and a majority of primary intracerebral haemorrhages [4] . Early diagnosis and appropriate therapy can prevent or delay the progress of VaD, and improve clinical outcomes, thereby making SVD an important target for treatment and preventive strategies [5] . The diagnosis of SVD is based on the characteristic triad observed by neuroimaging techniques like computed tomography or magnetic resonance imaging: lacunar infarct, microbleeds and leukoaraiosis [6] . Although these imaging modalities have facilitated the in vivo diagnosis of SVD, they are limited by the relatively high cost and inadequate availability in all treatment centres in developing countries like India. Consequently, there is a need for investigating novel biomarkers for reliable identification of SVD.
MicroRNAs (miRNAs), a class of small non-coding RNA molecules (19-24 nucleotides length), repress translation and regulate degradation of their target mRNA by binding to complementary regions of messenger transcripts [7] [8] . They are involved in the regulation of diverse cellular processes [9] [10] . MiRNAs present in bio-fluids are highly stable as they are protected by membranes in exosomes and other micro particles, as well as by different proteins and lipids. [11] . Recent studies have shown that miRNAs could serve as robust markers for detection of cancer, acute myocardial infarction and neurodegenerative diseases [12] [13] [14] [15] . Although studies have been conducted in cerebral large vessel disease, there is no information regarding circulating miRNAs as biomarkers for small vessel VaD.
In this exploratory study, an attempt was made to identify differentially expressed miRNAs in the plasma of patients with small vessel VaD and to evaluate their potential as biomarkers for the identification of this condition.
Materials and Methods

Study subjects
We recruited 204 patients (aged 65.1 ± 8.4 years) who presented to the Neurology Outpatient Department and the Geriatric Clinic of the National Institute of Mental Health and Neuro Sciences, Bengaluru, India, and were diagnosed with small vessel VaD. The control group consisted of 200 age-and gender-matched healthy, cognitively normal volunteers (mean age 64.6 ± 8.3 years). Approval was obtained from the Institutional Ethics Committee, National Institute of Mental Health and Neuro Sciences. A written informed consent was obtained from all participants. Selection criteria of study subjects are mentioned in our previous report [16] and in Supplementary data, Appendix I, available in Age and Ageing online.
Demographic data and biochemical investigations
The participants were reviewed by the neurophysician as per protocol. Demographic data, history of vascular risk factors and clinical details were recorded, and fasting venous blood collected. Further details are mentioned in Supplementary data, Appendix II, available in Age and Ageing online.
Extraction of miRNA from plasma samples and quality control analysis of miRNAs by quantitative PCR
Detailed information about miRNA isolation and quality control of miRNAs by quantitative polymerase chain reaction (qPCR) is mentioned in Supplementary data, Appendix III, available in Age and Ageing online.
Profiling and validation of plasma miRNA
Plasma miRNA profiling and validation were done by qPCR method. Details of analysis and miRNAs primers and spike-ins used in this study are provided in Supplementary data, Appendix IV, Table S1 , available in Age and Ageing online.
Statistical analysis
Statistical analysis was performed using SPSS v.21.0 (IBM Corporation Software Group, Somers, NY). Box-andwhisker plots and receiver operating characteristic (ROC) curves were generated using GraphPad Prism v.5.0 (GraphPad Software, Inc. CA, USA). Mann-Whitney U-tests were used to evaluate significance of differentiation of any two subject groups by various miRNAs. Biomarker potential was estimated by generating ROC curve and calculating the area under the curve (AUC) of each individual miRNA. MiRNA expression was expressed as mean ± standard error, P-value < 0.05 was considered statistically significant.
Results
Demographic and biochemical variables
Clinical and demographic data of the study subjects are depicted in Table 1 .
qPCR profiling of plasma miRNAs
The qPCR profiling of plasma miRNAs showed good signal-to-background ratios for 155 miRNAs. The principal component analysis of qPCR data showed that patient and control samples displayed divergent trends in signal intensity distributions, indicating altered miRNA expression profile in the patient group. Likewise, hierarchical clustering analysis demonstrated that the patterns of miRNA expression were distinct between patients and controls (see Supplementary data, Appendix V, Figure S1 , available at Age and Ageing online). Forty-four miRNAs were differentially expressed in small vessel VaD (22 upregulated, 22 downregulated) compared to controls (P < 0.05 with a fold change of <2 or >2), (see Supplementary data, Appendix IV, Table S2 , available at Age and Ageing online). Among them, seven miRNAs are having the highest fold difference (>3.6 or <3.6 fold) were selected for validation in a larger set of samples (upregulated: miR-363-3p, miR-451a, miR-486-5p, miR-502-3p, miR-32-5p and downregulated: miR-409-3p and miR-376a-3p).
Validation of differentially expressed miRNAs by qPCR
Differentially expressed miRNAs were validated in 200 controls and 204 patients. MiRNA expression in the validation cohort was found to follow the trend observed by qPCR profiling as shown in Table 2 (see Supplementary data, Appendix VI, Figure S2 and S3, available at Age and Ageing online).
To evaluate these differentially expressed miRNAs as potential biomarkers for small vessel VaD, ROC curve analysis was performed. The downregulated miRNAs (miR-409-3p and miR-376a-3p) differentiated patients from healthy controls with a sensitivity of 76% and 83%, and specificity of 89% and 71% with AUC of 0.94 and 0.85, respectively. The upregulated miRNAs, miR-32-5p, miR-502-3p, miR-486-5p, miR-451a and miR-363-3p showed a sensitivity of 51, 75, 75, 70 and 51% and specificity of 59, 89, 83, 75, and 70% and AUC was 0.58, 0.92, 0.90, 0.86 and 0.66, respectively (Table 2 , Supplementary data, Appendix VI, Figures S2 and S3 , available in Age and Ageing online). Combined ROC of all the seven miRNAs showed an AUC of 0.64 at 95% CI (0.61-0.67) with sensitivity of 55.5% and specificity of 65.7%.
Discussion
Cerebral SVD, a leading cause of VaD and a common accompaniment to ageing, results in severe disability and decreased quality of life [2, 17] . The diagnosis of SVD is challenging requiring neuroimaging studies. The availability of blood-based biomarkers could facilitate early diagnosis of this condition. MiRNAs which are relatively stable in the circulatory system may serve as molecular biomarkers for identification of disease status [12] .
Although many studies suggest that circulating miRNAs can differentiate patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) from cognitively normal controls [18] [19] , there is paucity of studies in patients with vascular cognitive impairment. In particular, there are no reports of miRNAs in cognitive impairment associated with cerebral SVD. In our study, miR-409-3p was significantly downregulated, and miR-502-3p, miR-486-5p and miR451a, upregulated, in small vessel VaD subjects compared to healthy, cognitively normal, controls. ROC analysis revealed that these miRNAs could serve as strong biomarkers for VaD due to SVD.
A study by Dong et al. [19] found that a panel of miR-31, miR-93 and miR-146a can differentiate AD from VaD, and miR-93 and miR-146a levels were higher in MCI subjects compared to controls. Another study by Sheinerman et al. [18] has shown that two sets of miRNAs: the 'miR-132 family' (miR-128/miR-491-5p, miR-132/miR-491-5p and mir-874/miR-491-5p) and the 'miR-134 family' (miR-134/miR-370, miR-323-3p/miR-370 and miR-382/miR-370) successfully detected MCI in a majority of AD patients at the asymptomatic stage prior to clinical diagnosis.
To the best of our knowledge, this is the first report of miRNAs in small vessel VaD. Our study is limited by the small sample size and the possibility of misclassification of patients as we used neuroimaging modalities for the diagnosis of SVD. Moreover, the concurrent presence of AD with VaD is not infrequent in older persons [20] and although we adopted Diagnostic and Statistical Manual of Mental Disorders -4th edition (DSM-IV), National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences and Hachinski Ischaemic Score scoring system to differentiate VaD from other neurodegenerative diseases we could not entirely discount a co-existing neurodegenerative disease with VaD because pathological confirmation was not feasible. In this pilot study, we identified four miRNAs which could serve as diagnostic biomarkers for small vessel VaD. Large-scale validation of their biomarker potential is warranted.
Key points
• Plasma microRNAs (miRNA) profiling showed divergent expression pattern between the study groups.
• Forty-four miRNAs were differentially expressed in small vessel vascular dementia (VaD) patients compared to healthy controls.
• miR-409-3p, miR-502-3p, miR-486-5p and miR-451a could be used as biomarkers for small vessel VaD. Circulating miRNAs in small vessel vascular dementia
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